

JUL 11 2002 #

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: June 28, 2002

Signature:

Shawn P. Foley
(Shawn P. Foley)

TECH CENTER 1600/2900

Docket No.: EGYPSA 3.0-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Legrain et al.

Application No.: 10/038,010

Group Art Unit: 1642

Filed: January 2, 2002

Examiner: Not Yet Assigned

For: Protein-Protein Interactions in Adipocyte Cells

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:


It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: June 28, 2002

Respectfully submitted,

By *Shawn P. Foley*
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorneys for Applicant



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/038,010		
		Filing Date	January 2, 2002		
		First Named Inventor	Pierre Legrain		
		Art Unit	1642		
		Examiner Name			
Sheet	1	of	2	Attorney Docket Number	EGYPSA 3.0-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	5468614	11-21-1995	Fields et al.	
	AB	4980286	12-25-1990	Morgan et al.	
	AC	5667973	09-16-1997	Fields et al.	
	AD	5283173	02-01-1994	Fields et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 00/66722	11-09-2000	Hybrigenics		
	BB	WO 99/42612	08-26-1999	Institut Pasteur		
	BC	WO 00/07038	02-10-2000	Universite de Montreal		
	BD	WO 98/34120	08-06-1998	Universite de Montreal		
	BE	WO 99/28746	06-10-1999	Institut Pasteur		
	BF	WO 92/06180	04-16-1992	University of Connecticut		
	BG	WO 93/14188	07-22-1993	The Regents of the University of Michigan		
	BH	WO 93/20221	10-14-1993	Alexander Young		
	BI	WO 96/34100	10-31-1996	Centre National de la Recherche Scientifique		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	ROBERT SERVICE "Protein arrays step out of DNA's shadow," 289 Science (2000) 16.	
	CB	MACBEATH & SCHREIBER, "Printing proteins as microarrays for high-throughput function determination," 289 Science (2000) 1760-63.	
	CC	ZIJLSTRA et al., "Germ-line transmission of a disrupted β 2-microglobulin gene produced by homologous recombination in embryonic stem cells," 342 Letters to Nature (1989) 435-38.	
	CD	WU & WU "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system," 262 J. Biol. Chem. (1987) 4429-32.	
	CE	JACOBY et al., "Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes," 4 Gene Therapy (1997) 1281-83.	
	CF	STEPHEN KOCHANNEK, "High-capacity adenoviral vectors for gene transfer and somatic gene therapy," 10 Human Gene Therapy (1999) 2451-59.	
	CG	MILLER et al., "Use of Retroviral Vectors for Gene Transfer and Expression," 217 Methods in Enzymology Recombinant DNA Part H (1993) 581-99.	
	CH	ROBBINS & GHIVIZZANI "Viral Vectors for Gene Therapy," 80 Pharmacology & Therapeutics (1998) 35-47.	

JUL 08 2002
PATENT

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 10/038,010

Filing Date January 2, 2002

First Named Inventor Pierre Legrain

Art Unit 1642

Examiner Name

Attorney Docket Number EGYPSA 3.0-002

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

Sheet

2

of

2

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CI	VASAVADA et al. "A contingent replication assay for the detection of protein-protein interactions in animal cells," 88 Proc. Natl. Acad. Sci. (1991) 10686-90.	
	CJ	TAKACS et al. "Mapping of interacting domains between the nucleocapsid protein and the phosphoprotein of vesicular stomatitis virus by using a two-hybrid system," 90 Proc. Natl. Acad. Sci. (1993) 10375-79.	
	CK	SZABO et al. "Surface plasmon resonance and its use in biomolecular interaction analysis (BIA) 5 Current Opinion in Structural Biology (1995) 699-705.	
	CL	PEARSON & LIPMAN "Improved tools for biological sequence comparison," 85 Proc. Natl. Acad. Sci. (1988) 2444-8.	
	CM	NEEDLEMAN & WUNSCH, "A general method applicable to the search for similarities in the amino acid sequence of two proteins," 48 J. Molecular Biology (1970) 443-53.	
	CN	SMITH & WATERMAN "Overlapping genes and information theory" Letter to the Editor, 91 J. Theoretical Biology (1981) 379-80.	
	CO	BRENT & FINLEY "Understanding gene and allele function with two-hybrid methods," 31 Annual Review of Genetics (1997) 663-704.	
	CP	LEGRAIN & SELIG "Genome-wide protein interaction maps using two-hybrid systems," 480 FEBS Letters (2000) 32-36.	
	CQ	VIDAL & LEGRAIN "Yeast forward and reverse 'n'-hybrid systems," 27 Nucleic Acids Research (1999) 919-29.	
	CR	EDWARDS & LEATHERBARROW "Determination of Association rate constants by an optical biosensor using initial rate analysis," 246 Analytical Biochemistry (1997) 1-6.	
	CS	GOLDSPIEL et al. "Clinical Frontiers; Human gene therapy," 12 Clin. Pharm. (1993) 488-505.	
	CT	FIELDS & SONG "A novel genetic system to detect protein-protein interactions," 340 Nature (1989) 245-6.	
	CU	REYNOLDS et al., "Chimeric viral vectors -- the best of both worlds?" Molecular Medicine Today (1999) 25-31.	
	CV	VIDAL et al. "Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions" 93 Proc. Natl. Acad. Sci USA (1996) 10315-20.	
	CW	TIRODE et al. "A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system," 272 J. Biol. Chemistry (1997) 22995-99.	
	CX	JEFFREY S. FLIER, "The adipocyte: storage depot or node on the energy information superhighway?" 80 Cell (1995) 15-18.	
	CY	ZHANG et al. "Positional cloning of the mouse obese gene and its human homologue," 372 Nature (1994) 425-32.	
	CZ	PELLEYMOUNTER et al, "Effects of the obese gene product on body weight regulation in ob/ob mice," 269 Science (1995) 540-43.	
	CA1	SALTIEL et al. "Thiazolidinediones in the treatment of insulin resistance and type II diabetes," 45 Diabetes (1996) 1661-69.	
	CB1	SREENAN et al., "Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone," 271 Am. J. Physiology (1996) E742-7.	
	CC1	NOLAN et al. "Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone," 331 New England J. Med. (1994) 1188-93.	
	CD1	TONTONOZ et al. "Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor," 79 Cell (1994) 1147-56.	
	CE1	LEHMANN et al. "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ)," 270 J. Biol. Chem. (1995) 12953-55.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.